Ruxolitinib (free base) | 10-042

Ruxolitinib (free base) | 10-042 | Gentaur UK, US & Europe Distribution

BNR: Chemical

Predicted Molecular Weight: 306, 4

Physical State: Lyophilized

Storage Condition: Short Term Storage: +4C. Long Term Storage: -20C. Handling Advice: Keep cool and dry. Use/Stability: Stable for at least 2 years after receipt when stored at -20C.

Alternate Name: INCB018424; INC 424

Background: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM) . Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19) .

Disclaimer: This product is for research use only.

Purity: greater than or equal to 98% (HPLC)

Formula: C17H18N6

Source: N/A

Solubility: Soluble in DMSO (>100mg/ml) and water (8mg/ml) . Slightly soluble in 100% ethanol.

InChi Key: HFNKQEVNSGCOJV-OAHLLOKOSA-N

Smiles: N#CC[C@H] (C1CCCC1) N1C=C (C=N1) C1=NC=NC2=C1C=CN2

RTECS: N/A

Identity: Determined by 1H-NMR and MS.

Merck Index: N/A